Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Megan Sykes
Columbia University Health Sciences, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Magenta Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Dr. Sykes is a consultant to Magenta Therapeutics ("MT") and holds stock options that will be vested in quarterly installments. (The equity amount listed above reflects the value of the shares after they are fully vested, based on current stock prices.) The company’s efforts may benefit from the outcome of the research under this grant. In light of these factors, Columbia has determined that the outcome of this research could affect the company and Dr. Sykes' financial interests in MT, and that the design, conduct, and/or reporting of this research could be affected by Dr. Sykes' interests in MT.
Robust allograft tolerance in non-human primates
Induction of tolerance to organ transplants would prevent all the complications, expense and limited efficacy associated with long-term immunosuppressive therapy. Non-myeloablative induction of transient mixed chimerism is effective in achieving tolerance for living donor kidneys but not for other types of donor organs or islets. We are exploring a strategy for achieving durable mixed chimerism, which achieves more robust tolerance and will be developed for applicability to all types of organs and islets and could also reverse inherited hematopoietic disorders with minimal toxicity.
Filed on July 10, 2019.
Tell us what you know about Megan Sykes's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Megan Sykes filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Megan Sykes | Columbia University Health Sciences | Conflict of Interest | Magenta Therapeutics | >$600,000 |
| Megan Sykes | Columbia University Health Sciences | Conflict of Interest | Magenta Therapeutics | >$600,000 |
| Megan Sykes | Columbia University Health Sciences | Conflict of Interest | Magenta Therapeutics | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.